SEC Form 4 · accession 0001209191-18-016866
SANGAMO THERAPEUTICS, INC · SGMO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curt A. Herberts III
Officer — Sr.VP & Chief Business Officer
Period of report
Mar 1, 2018
Accepted (ET)
Mar 5, 2018 · 6:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001233
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2018 | M | 171 | $12.12 | A | 14,796 | D | |
| Common Stock | Mar 1, 2018 | M | 1,430 | $9.41 | A | 16,226 | D | |
| Common Stock | Mar 1, 2018 | M | 8,087 | $14.07 | A | 24,313 | D | |
| Common Stock | Mar 1, 2018 | M | 5,312 | $3.50 | A | 29,625 | D | |
| Common StockF2,F3 | Mar 1, 2018 | S | 15,000 | $23.0574 | D | 14,625 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $12.12 | Mar 1, 2018 | M | 171 | D | — | Dec 11, 2023 | Common Stock | 171 | 0 | D |
| Stock Option (Right to Buy)F5 | $14.07 | Mar 1, 2018 | M | 8,087 | D | — | Dec 10, 2024 | Common Stock | 8,087 | 11,913 | D |
| Stock Option (Right to Buy)F6 | $9.41 | Mar 1, 2018 | M | 1,430 | D | — | Dec 7, 2025 | Common Stock | 1,430 | 17,320 | D |
| Stock Option (Right to Buy)F7 | $3.50 | Mar 1, 2018 | M | 5,312 | D | — | Jan 25, 2027 | Common Stock | 5,312 | 54,688 | D |
Explanation of responses
- F1All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.
- F2The price reported is a weighted average price. The shares were sold at prices ranging from $22.60 to $23.60 The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Includes (a) 8,375 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date; and (b) 6,250 shares subject to restricted stock units granted on December 8, 2015 that will vest on December 8, 2018, subject to the Reporting Person's continued service with the Issuer through such date.
- F4Fully vested and exercisable.
- F5One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 11, 2014 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
- F6One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 8, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
- F7The stock option vested and became exercisable for 25% of the shares upon the Reporting Person's completion of one year of service measured from the January 26, 2017 grant date, and the balance of the shares will vest and become exercisable in 36 successive equal monthly installments upon his completion of each additional month of service thereafter.